RCKT - Rocket Pharmaceuticals: Multiple Regulatory Submissions Make It A Must Watch
2024-04-02 14:34:13 ET
Summary
- EMA accepted Rocket Pharmaceuticals, Inc. regulatory application of RP-L102 for the treatment of patients with Falconi Anemia.
- A U.S. FDA BLA filing of RP-L102 for the treatment of patients with Falconi Anemia is expected in the 1st half of 2024.
- PDUFA date of June 30th of 2024 to determine if Kresladi should be approved for the treatment of patients with leukocyte adhesion deficiency-I.
- Rocket Pharmaceuticals had $407.5 million in cash as of December 31st of 2023; Enough cash to fund its operations into 2026.
Rocket Pharmaceuticals, Inc. ( RCKT ) is an ideal biotech to keep an eye on this year. That's because it has made advancements on several fronts in terms of possible regulatory approvals for its gene therapies. In particular, just today, it noted that the European Medicines Agency [EMA] just accepted its regulatory application of Lentiviral [LV] RP-L102 for the treatment of patients with Fanconi Anemia [FA]....
Rocket Pharmaceuticals: Multiple Regulatory Submissions Make It A Must Watch